The duration of the study for an individual patient will start from the signature of the main informed consent and include a screening period of up to 28 days, a treatment period [max 35 cycles {cohorts A1, A2, and B1} = 735 days or until PD {cohort C1}], an end-of-treatment visit at least 30 days following the last administration of study drug (or until the patient receives another anticancer therapy, whichever is earlier), and a follow-up visit 3 months after treatment discontinuation and every 3 months following, until disease progression, or initiation of another antitumor treatment, or death, whichever is earlier
Primary Objective:~-To determine the antitumor activity of SAR444245 in combination with other anticancer therapies.~Secondary Objectives:~To confirm the dose and to assess the safety profile of SAR444245 when combined with other anticancer therapies.~To assess other indicators of antitumor activity.~To assess the pharmacokinetic (PK) profile of SAR444245 when given in combination with pembrolizumab.~To assess the immunogenicity of SAR444245.